APA (7th ed.) Citation

M, B., HH, B., S, A., HA, A., H, A., H, A., . . . N, K. A. (2022). Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): An open-label, non-randomised, dose-escalation, phase 1b trial. The Lancet. Microbe, 3(1), e11. https://doi.org/10.1016/S2666-5247(21)00193-2

Chicago Style (17th ed.) Citation

M, Bosaeed, et al. "Safety and Immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults (MERS002): An Open-label, Non-randomised, Dose-escalation, Phase 1b Trial." The Lancet. Microbe 3, no. 1 (2022): e11. https://doi.org/10.1016/S2666-5247(21)00193-2.

MLA (9th ed.) Citation

M, Bosaeed, et al. "Safety and Immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults (MERS002): An Open-label, Non-randomised, Dose-escalation, Phase 1b Trial." The Lancet. Microbe, vol. 3, no. 1, 2022, p. e11, https://doi.org/10.1016/S2666-5247(21)00193-2.